Roderick de GreefChief Financial Officer
Roderick (Rod) de Greef has served as BioLife’s Chief Financial Officer since May of 2016. He was additionally appointed Chief Operating Officer in December 2019. Rod has a longstanding association with BioLife, having served as a director of the company from June 2000 through November 2013 and provided the company with strategic and financial consulting services from July 2007 through August 2011.
Due to his extensive experience in business and corporate finance, Rod is in high demand as an officer and director of public companies. He has served as a director and chairman of the Audit Committee of the Board of Directors of Indonesia Energy Corporation Limited since February 2019. Rod has twice served the mobile communications company Pareteum Corporation (2008-2011 and 2015-2017), as a director, Chair of the Audit Committee, and a member of the Nominating and Corporate Governance Committee and the Compensation Committee. Rod was Chairman of the Board at Cambridge Heart, Inc. from November 2008 to October 2013 and went on to serve as President and sole Director of that company’s privately held successor, Cambridge Cardiac Technologies, from November 2013 to October 2014. He served as a director, member of the audit committee and chairman of the compensation committee for Endologix, Inc. from November 2003 to May 2013. From 2001 to 2006, Rod was Executive Vice President and Chief Financial Officer of NASDAQ-listed Cardiac Science, Inc.
Rod has an MBA from the University of Oregon, and a B.A in Economics and International Relations from San Francisco State University.